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At the present time, it is recommended that the prostate cancer must be detected by digital rectal palpation (DRE) and PSA ele­
vation. TRUS coupled with ultrasonically guided biopsies might become the most appealing staging technique for early diag­
nosed prostate cancer.
To promote earlier diagnosis, better PSA thresholds need to be defined, with a clear free-PSA threshold. This could be com­
plemented by the use of nomograms and, in suspected cases, repeated biopsies, TRUS, bone scans and new imaging tech­
niques.
Deferred therapy, by means of an active observation and alertness to start therapy when signs of rapid progression occur, may 
therefore be an alternative to active therapy in patients with a low risk localized prostate cancer with a life expectance of 10 
years or less.
Radical prostatectomy was more effective than watchful waiting in terms of cancer-specific survival benefit, when compared 
in a prospective randomized trial.
Neoadjuvant hormonal therapy (NHT) has a non-significant impact on overall, and progression free survival.
In Europe the focus is on biochemical recurrence after a curative treatment (nerve sparing radical prostatectomy and/or radio­
therapy in low, intermediate and high-risk patients with 72-78 Gy.
In metastatic disease adjuvant androgen deprivation ADT Monotherapy is the treatment of choice. These are patients who can­
not be cured and some data suggest that intermittent hormone therapy can lead to a better life quality than a continuous one. 
The substantial reduction in pain and therapy related morbidity often makes chemotherapy with Docetaxel for hormone refrac­
tive prostatic cancer a better choice to a simple pain-and-complication treatment.
The article presents the summary of the essential features of each condition as well as its management.
Key words: Prostatic neoplasms - diagnosis, surgery, therapy; Treatment outcome; Neoplasms, hormone-dependent - drug ther­
apy; Androgen antagonist - therapeutic use; Antineoplastic agents, hormonal - therapeutic use; Drug therapy. Radiotherapy
Introduction
I would like to address reader’s attention to the paper, which 
defines in most cases, the point of view of the European 
Association of Urology (EAU) (1).
I tried to update the most recent literature that has appeared 
during the last years and hope to present the reader with a 
version of this complex field of medical science.
This is done in an effort to address the clinical challenges that 
confront the practicing urologist in the field of prostatic can­
cer.
Epidemiology
According to Cooperberg et al. (2) and Corica et al. (3) the 
incidence of prostatic cancer increases with the age of popu­
lation reaching a maximum prevalence of 33% in those aged 
>70 years (4). Prostate cancer is now the most commonly 
diagnosed malignancy in men, accounting for approximately 
2.6 million of cancers diagnosed annually in Europe. This 
disease accounts for 11% of all male cancers in Europe (5) 
and represents 9% of all deaths caused by cancer in the Euro­
pean Union. (6).
Risk of prostate cancer, etiology
It has been observed, for many decades, that more than one mem­
ber of the same family can be affected by the prostate cancer.
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Genetic basis and racial differences for this disease are well 
established, but the demonstration that familiar factors have 
epidemiological significance is difficult to obtain (7). An 
environmental factor can never be ruled out, insofar as many 
members of the same family may be exposed to an identical 
risk factor, not recognizable to an identical risk factor, which 
is not recognizable in most cases.
There was a higher risk with increasing number of affected 
family members (8). Men with 2 or 3 first-degree relatives 
with prostate cancer had respectively a 5 and 11-fold 
increased risk of developing the disease (9).
Carter et al. (10) reported that inherited prostate cancer 
should be suspected in men with onset of the disease before 
55 years of age or in males with 2 or more affected relatives.
Classification
The International Union Against Cancer (U1CC), 2002 TNM 
(Tumor, Node, Metastases), classification is used for staging
(1 1 ).
There are several systems of classification of the tumor 
grade. The most commonly used for grading the adenocarci­
noma of the prostate is the Gleason's system (12).
Gleason’s grading system is based on the analysis of various 
microscopic criteria of the tumor at low power magnification, 
which are divided into 5 appearances, scored from 1 to 5. As 
the tumor does not have a uniform appearance, this system 
takes account of the two most extensive appearances, in 
terms of the area (primary and secondary patterns). If a tumor 
contains smaller areas of other appearances, they are not 
taken into account in the final histological grade, even if one 
of them corresponds to a more poorly differentiated pattern. 
The histological grade is the sum of the two histological pat­
terns defined or twice the score the simple pattern detected. It 
is therefore scored from 2 to 10. To be counted a pattern 
(grade) needs to occupy more than 5% of the biopsy (core or 
operative specimen). Gleason’s system results in a histologi­
cal score which is closely correlated to a patient’s survival 
(13).
Screening and early detection
The demand for a routine preventive cancer checkup is based 
on the oncological principle that all diseases have a better 
chance of cure if they are detected and thus treated at an early 
stage (14).
Population or mass screening is defined as the examination of 
the asymptomatic male (at risk).
In addition, the principle also implies that screening current­
ly includes a study and is initiated by a screener. Contrary to 
that, early detection represents individual case findings. It is 
initiated by the patient and/or his physician.
Reduction in mortality from prostatic carcinoma shows a 
wide variety worldwide all over the industrialized countries
(15).
Screening for prostate cancer is based on the assumption that 
it is a relevant public health concern. Prospective, preferably 
population-based, randomized studies are still required. 
Finally, two studies are underway, the PLCO (Prostate, Lung, 
Colorectal and Ovary) trial in the USA and the ERSPC (Euro­
pean Randomized Screening for Prostate Cancer) in Europe
(16).
First results of these trial differences in cancer mortality are 
scheduled for 2013 and 2008 respectively.
Thus, at the present time, there is a lack of evidence to sup­
port or disregard screening programs. For prostatic carcino­
ma it can be said that none of the two randomized trials have 
been completed demonstrating that early detection results in 
diminished prostate cancer deaths.
Undoubtedly there are as many prostate cancers now detect­
ed by PSA elevations without digital rectal abnormalities as 
there are cancers detected through a positive digital rectal 
examination (17).
Until the last two decades this was a relatively straight for­
ward consideration and less controversial as digital rectal 
examination, and PSA was the mainstay of early identifica­
tion of prostate cancer (18).
Diagnosis and staging
At the present time, it is recommended that a cancer must be 
detected by digital rectal palpation (DRE) and PSA elevation 
(19, 20, 21, 22).
TRUS coupled with ultrasonically guided biopsies might 
become the most appealing staging technique for early diag­
nosed prostate cancer.
To promote earlier diagnosis, better PSA thresholds need to 
be defined (1 8).
Aus et al. (23) described the cumulative 7-year risk of being 
diagnosed with carcinoma of the prostate in a screening pro­
gram based on PSA measurement. Summarizing these 
results, the ranges of increased PSA activity was only 34% 
for men with PSA levels between 3 and 6 ng/ml, 44% for 
those patients with PSA values between 6 and 10 ng/ml, and 
71% for those patients with PSA values > 10 ng/ml.
Thompson et al. (24) observed that many men may harbor 
prostatic cancer despite low values of PSA has been under­
scored by recent results from the US prevention study.
An important question concerning clinical practice, a free-to- 
total PSA ratio of < 20% and PSA velocity > 0,75 ng/ml/year 
have been accepted as valid parameters, which are associated
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with an increased risk of the prostate carcinoma (25). Up to 
now, 12.078 men undergoing a prostatic biopsy were fol­
lowed in a recent retrospective study. Threshold values of 
PSA and PSA velocity were identified to improve the assess­
ment of the prostate carcinoma risk in men beyond the age of 
50 (26). Extensive studies show that the prevalence of the 
prostate carcinoma was 4,4% and 14,2% in men beyond 50 
years and older than 50 years respectively.
According to this data, a PSA threshold level of >2,5 ng/ml 
and a PSA velocity threshold level >0,60 ng/ml/year seems to 
be appropriate for clinical practice.
The ultra sound-guided transrectal 18G core biopsy won gen­
eral acceptance and has become a standard way of obtaining 
tissue from the prostate for histopatological examination 
(27). According to the experience gained from several studies 
it is possible to show a higher cancer detection rate in an 
extended 21-sample biopsy compared to the standard sextant 
technique (28, 29). Most of the studies clearly show that the 
transition zone should not be the target area for the first set of 
prostate biopsies. An overall accuracy of 2% cancer detection 
rate is to be expected (30, 31).
According to author’s experience if the first set of biopsies is 
negative, repeated biopsies can be recommended. The sec­
ond set of biopsies exhibit a detection rate of about 10-35% 
(32).
It is a known fact that in cases where high-grade prostatic 
intraepithelial neoplasia (HGPIN) or atypical small acinar 
proliferation (ASAP) is present, as many as 50%-100% of 
prostates will suggest carcinoma. Clinical follow-up and 
repeated biopsies are indicated (33, 34).
Primary treatment of prostate cancer
Early prostate cancer management 
Surgery, radiation or active surveillance?
Different urologists have their own special methods for deal­
ing with presumed localized prostatic cancer. These addition­
al methods include watchful waiting (35), immediate 
endocrine therapy, and external and/or interstitial radiation. 
The important thing is the absence of metastases. When they 
are absent, any treatment that completely removes or destroys 
the primary growth will result in cure, and when metastases 
are present, none is likely to do so. When making such deci­
sions, many physicians rely on nomograms based on pre­
operative biochemical markers and biopsies (36).
Watchful waiting (active surveillance)
The efficacy of different types of treatment for localized 
prostate cancer has come under question. While radical 
prostatectomy and radiotherapy have been associated with 
low progression rates and high survival figures, it is well 
known that in many patients the cause of death is not prostate 
cancer. Therefore, there is a renewed interest in studying the
natural history of this disease to better appreciate the extent, 
to which active forms of treatment may alter the outcome (37, 
38).
Deferred therapy, by means of active observation (39) and 
alertness to start therapy when signs of rapid progression 
occur (40), may therefore be an alternative to active therapy 
in patients with low risk localized prostate cancer with a life 
expectance of 10 years or less (41).
Chodak et al. (37) and Albertsen et al. (38) observed an 80- 
90% cancer specific survival with a deferred therapy treat­
ment after a follow-up of 20 years.
The excellent article of Chodak et al. (37) described the out­
come for stage T1 a patients, with cancer-specific 10-year sur­
vival rates of 90%.
Classification of the Gleason score, stage and PSA level on 
the risk of tumour progression and ultimately death trom 
prostate cancer are mandatory.
Klotz et al. (42) observed in a series that patients with a 
PSA<10 ng/ml, biopsy Gleason score < 6, stage cTlc-cT2a, 
live expectancy <10 years should be managed expectantly. 
All authors reporting on deferred treatment for presumed 
localized prostate cancer (Nx-No, Mo) stage Tla - well -and 
moderate differentiated tumours, with a life expectancy of 
>10 years, re-evaluation with PSA, TRUS and biopsies of the 
prostatic remnant is necessary.
Indications for radical prostatectomy
Objectives of RPE
The selection of patients for radical curative procedures put 
the urologist in a dilemma about attempting to maintain both, 
the quality of life and the duration of survival of the patient 
(43, 44).
Radical prostatectomy for the treatment of prostate cancer 
can be performed by various techniques using a retropubic, 
perineal or laparoscopic approach (45, 46, 47, 48, 49, 50).
Current data would indicate that nerve sparing radical prosta- 
tovesiculectomy is the most effective way of dealing with 
adenocarcinoma of the prostate, which is organ-confined 
within the anatomic margins of the prostate gland. The expe­
rience with radical prostatectomy was more effective than 
watchful waiting in terms of cancer-specific survival benefit 
(35), when compared in a prospective randomized trial.
Pelvic lymphadenectomy?
The addition of pelvic lymphadenectomy should allow the 
clinician to assess with greater accuracy the possible pres­
ence of extended disease (51).
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Besides being a staging procedure, extended pelvic lymph 
node dissection might be curative, or at least beneficial in a 
group of patients with limited lymph node metastases (52, 53, 
54).
According to Partin nomograms (36) patients with cT 1 c, PSA 
value< 10 ng/ml and biopsy Gleason score < 6 have a low risk 
of metastatic disease in the pelvic lymph nodes, therefore 
additional advantage of removing lymph nodes might not be 
necessary.
In patients with intermediate risk (cT2a, PSA value 10-20 
ng/ml, biopsy Gleason score =7), or high risk (>cT2b, 
PSA>20 ng/ml, biopsy Gleason score>8), the presence of 
pelvic nodal metastases is elevated. The addition of an 
extended lymphadenectomy is necessary (51). Joniau et al. 
(55) reported an incidence of 13-27% of overstaging in 
patients with clinical T3 carcinoma.
Treatment results of clinical cT3 adenocarcinoma of the 
prostate with radical prostatectomy: These results have been 
satisfactory. Locally advanced disease can be treated suc­
cessfully with radical prostatectomy with a satisfactory over­
all survival at 5,10 and 15 years and a cancer-specific sur­
vival of 95%, 90% and 79%, respectively (55, 56, 57, 58, 59).
Possible beneficial effect of adjuvant hormonal treatment: 
Neoadjuvant hormonal therapy (NHT) has been used to facil­
itate radical prostatectomy, and reduce the risk of leaving 
cancer behind (60).
To the contrary, a Cochrane review and meta-analysis 
observed a non-significant impact on overall, and progression 
free survival (61).
Androgen deprivation after radical prostatectomy has been 
controversially discussed (62, 63).
In the only published prospective randomized study by Mess­
ing et al. (64) early adjuvant therapy after radical prostatec­
tomy with nodal involvement provide a significant survival 
advantage.
Despite this report of spectacular results, this approach might 
be flawed for several reasons. Firstly, large tumours seem to 
consist of a high percentage of macroscopic lymph node 
involvement, and 70% of the patients have evidence of surgi­
cal margin-positive disease or seminal vesicle involvement. 
Secondly, there is no evidence that microscopic lymph node 
involvement perse will have a positive impact on a disease 
outcome.
The detailed investigations of the Early Prostate Cancer Trial 
show that the progression free survival is not evident in 
patients with prostate cancer after standard therapy with addi­
tionally 150 mg bicalutamid daily. To the contrary, they 
observed a favourable impact on overall survival in patients 
with locally advanced prostatic carcinoma (62).
Radiation therapy (DxT)
The effect of dose escalation and additional 
hormonal therapy
With the use of dose escalation radiation therapy it has 
become possible to deliver a better outcome in patients with 
prostatic cancer.
Kupelian et al. (65) utilize external radiation in patients with 
low risk prostate cancer with a dose of >72Gy or< 72Gy. 
After irradiation, biochemical disease-free survival is statisti­
cally significantly better 69% vs 63% in patients with 
increased external irradiation.
Improvement of prognosis of patients with intermediate risk 
cTlc-T3 could be achieved by higher doses ranging from 76 
to 81 Gy. Zelefsky et al. (66) observed a significant improve­
ment in 5-year survival without biochemical relapse. These 
clinicians usually apply a dose of 78Gy. Combination with 
adjuvant hormonal treatment lor 6 months after receiving 
external radiation of 72Gy improved the results.
Poliak et al. (67) published results of a randomized radio­
therapy dose-escalation trial comparing 70Gy with 78Gy. 
From these data it is evident that in cases with high risk 
prostate cancer radiotherapy dose- escalation improves 5 year 
biochemical disease-free survival (68,69,70). In fact their 
data demonstrate that patients receiving an adjuvant andro­
gen deprivation (ADT) and external irradiation have 
improved biochemical disease-free survival. It even cannot 
be excluded that a proportion of these patients have a relapse 
outside the pelvis. Bolla et al. (71,72) could establish that 
eoadjuvant and adjuvant hormonal therapy for two years is 
mandatory for patients undergoing irradiation in the igh-risk 
group (73, 74, 75, 76, 77, 78).
Transperineal brachytherapv
The interest in intraprostatic implantation of radioactive 
material revived in the second half of the last century when 
urologists made it evident that hormone therapy was not the 
ideal approach in nonmetastasized prostatic cancer (79).
Ash et al. (80) published transperineal brachytherapy in 
growths limited to the prostate (category stage cTlb-T2aNo, 
Mo, a Gleason score<6, in enough cases of histologically 
proven number of random biopsies.
A good International Prostatic Symptom Score (IPSS) with 
an initial PSA level of<10 ng/ml, <50% of biopsy cores 
involved with prostatic cancer on a gland volume of<50cml 
is mandatory.
Machtens et al. (81) reported in a paper recurrence-free sur­
vival data of patients treated with permanent seed implants. 
After 5 and 10 years they range from 71% to 93% and from 
65% to 85% respectively.
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Up to the present time there is no benefit from combining 
neoadjuvant or adjuvant deprivation to low-dose rate (LDR) 
brachytherapy.
Nevertheless, a number of complications have been reported 
following brachytherapy, such as urinary retention (1.5- 
22%), post-implant TURP (about 8.7%) and incontinence (0- 
19%) as acute urinary symptoms.
In addition to the acute manifestations chronic urinary mor­
bidity might occur in about 20% of patients associated with 
symptoms before to therapy.
Radiation therapy pT3, pTxRl
Immediate or delayed radiotherapy after radical prostatec­
tomy?
The presence of positive margins after radical prostatectomy 
correlates with detectable post-operative elevation of PSA. 
Although the presence of an elevated PSA following radical 
prostatectomy, denotes residual disease, one has to reconcile 
the fact that only 7-10% of patients following radical prosta­
tectomy will develop clinical local recurrence (82).
A significant difference between two groups of patients (pos­
itive vs. negative margins) was found according to preopera­
tive and postoperative Gleason score as well as according to 
T-staging (83).
The results of this modality approach (immediate postopera­
tive radiotherapy) are presented in three randomized trials 
(84).
In the data presented (EORTC study, 22911) clinical or bio­
logical 5-years survival has been significantly improved 
(72.2% vs. 51.8%) in the immediately adjuvant radiotherapy 
group (60 Gy) to radiotherapy delayed until local recurrence 
(70 Gy) in patients after radical retropubic prostatectomy.
The radiation effect is limited. It has not been seen that this 
treatment modality improves metastases-free survival and 
carcinoma specific survival in this group of patients.
The question that arises is should all patients with positive 
surgical margins be treated with immediate adjuvant radia­
tion therapy in an attempt to prevent recurrence? From this 
data it is evident that immediate radiation therapy should be 
the treatment of choice in cases with multifocal positive sur­
gical margins and a Gleason score >7, or patients with a PSA 
level >0.1 ng/ml one month after radical prostatectomy.
Alternative therapeutic options
Radical prostatectomy has remained the reference standard 
treatment for localized prostate cancer. Surgery of the 
prostate cancer provides histological evidence of complete 
tumor removal, including margin status. The lack of histo­
logical proof of complete tumor ablation is an inherit disad­
vantage of all ablative technologies.
However, with cryoablation, the ability to achieve real-time 
ultrasound imaging of the iceball appears to overcome this 
challenge.
Besides external beam radiation and/or brachytherapy 
cryosurgical ablation of the prostate (CSAP) and high-inten- 
sity focused ultrasound (HIFU) has recently become avail­
able alternative therapeutic modalities in cases with localized 
prostate cancer (85).
The ideal patients for crioablation (CSAP) are those with 
organ-confined prostate cancer. Prostate volume should 
be<40 ml. PSA serum levels should be<20 ng/ml and the 
biopsy Gleason score should be<7.Long-term follow -up of 
10 and 15 years is the final step needed to definitively deter­
mine the role of cryosurgical ablation in the treatment of 
localized prostate cancer. In general the treatment population 
included patients with a life expectancy>10 years, therefore 
tr atment options must be discussed with the patients.
Management of advanced prostate cancer
Hormonal therapy, controversies of palliative hormonal 
treatment
Most authors agree that medical castration is probably better 
achieved today by the depot administration of long-acting 
LHRH analogues. Randomized trials have shown that these 
drugs are as effective as orchidectomy or 3 mg diethylstilbe- 
trol (DES) daily. The physiological surge of testosterone 
induced by the initial LHRH analogues administration can be 
countered by the administration of an antiandrogen given for 
1 week prior to LHRH agonist and continued during the first 
month of therapy.
The most direct technique for lowering plasma androgen lev­
els is bilateral orchidectomy, removing the primary source of 
testosterone in male patients for a life time. Medical castra­
tion was achieved by the oral administration of (DES) daily. 
A number of studies confirmed its efficacy for cancer control 
but revealed significant cardiovascular toxicity and associat­
ed mortality (86, 87, 88).
In the meantime at least two prospective randomized trials 
addressed the question of monotherapy with Bicalutamid 
(150 mg/daily) vs. medical or surgical castration including 
1435 patients with locally advanced Mo or widespread dis­
ease Ml prostatic carcinoma are available (89).
Some essential data of this study are briefly summarized 
herein. With respect to the M 1-category patients, an improve­
ment in overall survival with castration is present, although 
the difference in median survival between the two groups was 
only 6 weeks. These authors concluded that non-steroidal 
antiandrogens in contrary to steroidal antiandrogens could be 
a therapy alternative and may be recommended. A survival
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benefit only for patients with higher PSA level > 400 ng/ml 
has been observed (90). No significant difference in overall 
survival occurred in the Mo- category.
Complete androgen blockade (CAB)
The clinical introduction of anti-androgens as second line 
hormonal treatment after failure of the initial castration fur­
ther confirmed additional patient responses ranging from 6 to 
15% (91).
The idea to move this clinical response up front by combin­
ing both therapies was first experimented by Bracci utilizing 
cyproterone acetate (CPA) and by Labrie utilizing flutamide 
at the time of initial treatment (92, 93).
The review of the available data, and the cumulative meta­
analysis of the leading investigators and clinical groups who 
had studies on the value of complete androgen blockade vs. 
monotherapy in the treatment of advanced prostate cancer 
served as a basis for an extensive discussion (94).
After a follow- up of 5 years the response results in favour of 
the combination were published by Seidenfeld and Iversen 
(86, 89). The study suggests an improvement less than (<5%) 
in survival with the combination treatment.
Intermittent androgen suppression (IAS)
No other treatment exists that equals or surpasses androgen 
ablation in controlling the growth of prostate cancer. Approx­
imately 80% of prostate cancer patients achieve symptomatic 
and objective responses following androgen suppression, and 
serum prostate specific antigen (PSA) levels decrease in 
almost all patients. However, for reasons that remain 
unknown, the cell death process induced by androgen abla­
tion by whatever means fails to eliminate the entire malignant 
cell population (95) and after a variable period of time aver­
aging 24 months, tumours inevitably recur with increasing 
serum PSA levels and are characterized by androgen inde­
pendent growth. Experimental and early clinical experience 
with intermittent androgen suppression (IAS), suggest that 
quality of life (QOL) is improved and progression to andro­
gen independence may be delayed using reversible androgen 
suppression and PSA as the trigger point. IAS may offer a 
“way out” of the immediate versus delayed treatment contro­
versy., by balancing the benefits of immediate androgen abla­
tion with reduced treatment-related side effects and expense. 
The effects of intermittent therapy have also been tested in 
several phase II trials showing the feasibility of intermittent 
androgen suppression (IAS) in metastatic disease.
Available information about IAS is still very limited. For 
intermittent vs. continuous therapy the SWOG trial 9346 ran­
domized, 1134 men with stage D2 prostate carcinoma. After 
7 months induction with ADT with PSA levels decrease 
<4ng/ml (96). Finally it is clear that a PSA reduction to <0.2 
ng/ml,<4ng/ml and >4 ng/ml was identified as a significant 
prognostic factor with regard to survival, achieving 13
months, 44 months and 75 months, respectively, and no sig­
nificant differences with regard to survival were seen 
between treatment groups. In conclusion, IAS is a relevant 
option for patients with prostate carcinoma
In conclusion, IAB is at present widely offered to patients 
with CaP in various clinical settings. However, many aspects 
need to be clarified, such as timing, duration and type of 
treatment.
Delayed or immediate hormonal therapy (ADT)?
An extensive overview of hormonal treatment, and the timing 
to introduce therapy in patients with advanced prostatic car­
cinoma is controversial, in particular whether androgen 
blockade for locally advanced disease and asymptomatic 
metastatic disease delivered immediately at diagnosis 
favourably influences survival and QOL compared to delayed 
ADT while signs and symptoms of clinical progression 
remain controversial.
There are three studies currently available for reviewing the 
issue of early vs. deferred treatment. No prospective random­
ized trials are available.
There is only one retrospective study using biochemical tests 
and standardized follow-up schedules, including 1352 
patients after radical prostatectomy with a rising PSA levels 
after therapy (97).
According to the analysis, immediate androgen ablation con­
ducted in the post-PSA era in patients with advanced prostate 
cancer who received immediate (MO) vs. deferred ADT (Ml) 
are presented. In both patients groups there is no significant 
advantage in overall and carcinoma-specific survival. Imme­
diate androgen therapy provides a benefit in patients with a 
Gleason- score >7 or a PSA doubling time<12 months.
The significance of rising PSA after a treatment with 
curative intent
While one can take comfort in a falling PSA after radical 
prostatectomy or irradiation of prostatic cancer, a rising PSA 
is cause for considerable concern (98); noted that PSA levels 
of >0.2 ng/ml after radical prostatectomy were related direct­
ly to a biochemical recurrence(recurrence of prostate cancer). 
The new definition of radiation failure can be defined as a 
rise of 2 ng/ml above the post-treatment PSA-nadir (lowest 
value). Roach et al (78) correlated it with a recurrence in men 
with clinically localized prostate cancer.
In conclusion, it is possible that distant dissemination may 
develop secondly to local failure. The existence or re- growth 
of local residual disease in localized prostatic carcinoma pro­
motes and enhances spread of metastatic disease.
The probability of distant metastases is related to the stage of 
the tumor, the grade of the tumor and the PSA level pre and
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post treatment. Relapsing patients however were those with 
short PSA doubling time, advanced stage unfavorable Glea­
son scale and rapidly increasing PSA level. For the most part 
these patients would have a metastatic disease. The PSA dou­
bling time (>10-12 month) and slowly PSA increase correlate 
with a local recurrence.
On the other hand these patients might have benefited from 
more vigorous initial treatment such as is possible with a rad­
ical prostatectomy, radiation or perhaps androgen deprivation 
as an adjunct to irradiation.
Both bone scintigraphy and CT may be helpful and remains a 
sensitive method to detect a recurrence if the serum PSA level 
is >20 ng/ml, particularly when PSA velocity is >2 ng/ml/ 
year.
Additionally endorectal MRI may be helpful for detecting a 
recurrence if PSA level is>2 ng/ml.
Finally new antibody radiolabelled scintigraphy and PET 
techniques may provide more accurate information for 
detecting recurrent or metastatic disease of the lymph nodes 
in the future .Thus more studies are needed to investigate or 
evaluate those techniques, before they can be recommended 
for routine use in clinical practice (99).
Treatment of hormone-resistant prostatic cancer
Although the majority of patients (70%) with prostatic cancer 
respond objectively and/or subjectively to hormone treat­
ment, an escape phenomenon occurs after an average of 2 to
3 years (52).
Flormone-resistant stage T3 or M+ prostatic cancer is defined 
by the fact that the disease continues to progress despite a 
well conducted hormone treatment.
Non -compliance with the treatment regimen (often seen in 
elderly men) should be ruled out, by the observation of cas­
trate level serum testosterone, as the main reason for treat­
ment failure.
This escape results from selection of preexisting or de novo 
appearance of hormone resistant clones.
What is the definition of progression?
Classically, definition of failure of the primary treatment and 
progression was based on clinical criteria. Now that PSA has 
been shown to be a good marker of tumour progression, we 
have to consider that the primary treatment has failed as soon 
as PSA starts to rise again. These biological changes precede 
clinical progression by several months.
At the present state of our knowledge, the precise definition 
of recurrent or relapsed prostate carcinoma remains contro­
versial. The current literature is reviewed, regarding hor­
mone-resistant carcinoma. Androgen-independent, but hor­
mone-sensitive prostate carcinoma, has to be differentiated 
from true HRPC from the outset. In practice the first group 
still responds to secondary hormonal manipulations, such as 
antiandrogen withdrawal, oestrogens and corticosterids, the 
second group is resistant to all hormonal measures (100).
Second line hormonal treatment 
When should a second line hormonal treatment 
be considered?
An alternative treatment must be considered when the level 
of PSA starts rising, when new spots appear on follow-up 
bone scan and of course when the patient becomes sympto­
matic again. The longer we wait the less effective will be the 
second line hormone therapy.
When a cancer is resistant to a primary hormonal treatment, 
can it still respond to another hormonal treatment? At pres­
ent there are multiple therapeutic options for second line 
endocrine management available.
We already know that our capacity to prolong survival is lim­
ited and this means that our choice for second line therapy 
should aim more at improving the quality (QOL) than the 
duration of survival, taking into consideration the patients 
specific expectations and wishes.
Which endocrine therapy to choose is determined by factors 
which are depending on the patient, the tumour and the first 
line therapy and is given by a therapeutic algorithm (101).
When a metastatic prostate cancer is resistant to LHRH ana­
logues, subcapsular orchiectomy, CAB or anti-androgen 
monotherapy (mean duration of response 36 months) it can 
still respond to another hormonal treatment.
When the patient relapses the addition of anti-androgens, 
LHRH-analogues or addition of LHRH-analogues in 
monotherapy, a response can be obtained in some cases 
(mean duration of response 4-6 months) in the presence of 
resistance to standard hormonal therapy.
Are there any other hormonal modalities?
Antiandrogen withdrawal responses have also been reported 
after treatment with bicalutamide and flutamide (102, 103) 
with a median duration of response of approximately 4 
months. Alternative treatments other than hormones? The 
benefits of a secondary hormonal manipulation such as adre­
nal testosterone inhibitors low-dose DES, steroids or non- 
hormonal therapy such as chemotherapy seems to result in 
declining PSA in a group of patients.
Treatment options after true hormonal treatment failure are 
chemotherapy. Cytotoxic therapy
The efficacy of Docetaxel in the treatment of patients with 
(HRPC) was evaluated.
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Painful metastases treatment
The substantial reduction in pain and therapy related mor­
bidity frequently makes chemotherapy for hormonal refrac­
tive prostate cancer a better alternative to simple pain and 
complication treatment (104).
A significant improvement in median survival of approxi­
mately two months could be demonstrated for Docetaxel with 
Prednisolone as compared with mitoxantrone plus prednisone 
in the management of hormone-resistant prostate cancer 
(HRPC) in two prospective randomized clinical Phase III tri­
als. The influence of Docetaxel achieves a significant 
improvement in pain and quality of life (QOL) in this trial. 
The results of the treatment outlined above demonstrate a 
PSA decline in 45% compared to 32% in the mitoxantrone 
group (105, 106).
The following conclusions can be drawn from these publica­
tions: Docetaxel had a beneficial effect in the treatment of 
true (HRPC) and becomes treatment of choice in refractory 
carcinoma of advanced stage.
Role of chemotherapy
The beginning of the treatment with chemotherapy of patients 
with advanced refractory prostate cancer is not well defined.
In practice, these patients suffer from their bone metastases. 
We shall not discuss painless metastases with PSA relapse 
which do not require any particular treatment apart from that 
of the primary tumor. However, spine and hips disseminated 
asymptomatic metastases must be watched and treated for 
possible pathological fractures. In the case of a localized or 
disseminated symptomatic metastasis, the best treatment 
remains chemotherapy.
Palliative therapeutic options 
(radiotherapy, cortisone, analgetics and 
antivomiting drugs)
If the patient does not like chemotherapy, classical palliative 
treatment must be prescribed. The action of radiotherapy, 
which is a local treatment, is limited in the case of dissemi­
nated lesions and when the origin of the pain is difficult to 
determine.
Patients treated by this method are generally at the terminal 
stage of the disease. Analgesia has been achieved in a large 
number of cases but it is difficult to evaluate the duration as 
these patients often die soon after this irradiation probably, 
because of their already severely impaired status.
Very good results have been published in the literature with 
bisphosphonates in order to prevent skeletal complications 
(107, 108).
We are left with non-specific analgesia, which has progressed 
considerably over recent years. The treatment of a patient 
with advanced disseminated metastases involves the simulta­
neous administration of high doses of morphine and high 
doses of non-steroidal, then steroidal anti-inflammatory 
agents.
Zoledronic acid, is an excellent analgesic for multiple bone 
pain. As a result of these advances, pain can be controlled in 
the majority of patients.
Conclusions
As an international community, urologists are not only strug­
gling with the dilemma of helping a patient to decide on an 
optimal treatment plan, but they also have to deal with the 
uniqueness of their patient population, the availability of 
technology, and the practice biases of their colleagues.
In the area of prostate cancer, there are many clinical situa­
tions which have more than one treatment option. Rather, the 
essential features of each condition and its management are 
summarized.
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UPUTE VEZANE UZ DIJAGNOZU I TERAPIJU KARCINOMA PROSTATE:
KONTROVERZE U UROONKOLOGIJI
Carlos D. M. Winkler
Klinika za urologiju i pedijatrijsku urologiju AKH, Celle
SAŽETAK
U današnje se vrijeme preporuča otkrivanje karcinoma prostate digitalnom rektalnom palpacijom (DRE) i PSA elevacijom. 
TRUS bi zajedno s ultrazvučno vođenim biopsijama mogla postati najkorisnija tehnika za rano otkrivanje karcinoma prostate. 
Kako bi se dijagnoza postavila što prije, moraju se definirati bolje granice PSA s jasnim slobodnim graničnim vrijednostima 
PSA. To može biti upotpunjeno upotrebom nomograma i u spornim slučajevima ponovljenim biopsijama, TRUS postupkom, 
skeniranjem kostiju i novim tehnikama oslikavanja.
Odgađanje liječenja uz aktivno promatranje i spremnost na početak terapije, kada se pojave znakovi progresije, mogu biti alter­
nativa aktivnoj terapiji u pacijenata s lokaliziranim karcinomom prostate niskoga rizika uz očekivani životni vijek od 10 go­
dina ili manje.
Radikalna je prostatektomija, kada se usporedi u očekivanoj randomiziranoj studiji, bila učinkovitija od čekanja uz promatranje 
u smislu preživljenja specifičnoga za rak.
Neoadjuvantna hormonalna terapija (NHT) nema značajniji utjecaj na ukupno preživljenje bez napredovanja bolesti.
U Europi naglasak je na biokemijskom povratu bolesti nakon liječenja (Radikalna prostatektomija uz poštedu živaca i/ili 
radioterapija kod niskorizičnih, srednjerizičnih i visokorizičnih pacijenata s 72-78 Gy).
Kod bolesti koja je metastazirala izabire se adjuvantna deprivacija androgena ADT monoterapija kao metoda liječenja. To su 
pacijenti koji se ne mogu izliječiti i neki podaci ukazuju da intermitentna hormonalna terapija može dovesti do bolje kvalitete 
života od konstantne. Kemoterapija s Docetaxelom za liječenje hormonskoga karcinoma prostate često je bolji izbor od jed­
nostavnoga liječenja boli i komplikacija, zbog značajnijega smanjenja smrtnosti uzrokovane boli i liječenjem.
Sažete su osnovne karakteristike svakog stanja i upravljanja njime.
Klj učne riječi: Tumori prostate - dijagnoza, operacija, liječenje; Ishod liječenja; Tumori, hormonski ovisni - terapija lijekovi­
ma; Androgeni antagonisti - terapijska upotreba; Protutumorski lijekovi, hormonski - terapijska upotreba; Terapija lijekovima; 
Radioterapija
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